Assessing the Quality of the Steps to Reproduce in Bug Reports

A major problem with user-written bug reports, indicated by developers and documented by researchers, is the (lack of high) quality of the reported steps to reproduce the bugs. Low-quality steps to reproduce lead to excessive manual effort spent on bug triage and resolution. This paper proposes Euler, an approach that automatically identifies and assesses the quality of the steps to reproduce in a bug report, providing feedback to the reporters, which they can use to improve the bug report. The feedback provided by Euler was assessed by external evaluators and the results indicate that Euler correctly identified 98% of the existing steps to reproduce and 58% of the missing ones, while 73% of its quality annotations are correct.Comment: In Proceedings of the 27th ACM Joint European Software Engineering Conference and Symposium on the Foundations of Software Engineering (ESEC/FSE '19), August 26-30, 2019, Tallinn, Estoni

ARENA: An Approach for the Automated Generation of Release Notes

Release notes document corrections, enhancements, and, in general, changes that were implemented in a new release of a software project. They are usually created manually and may include hundreds of different items, such as descriptions of new features, bug fixes, structural changes, new or deprecated APIs, and changes to software licenses. Thus, producing them can be a time-consuming and daunting task. This paper describes ARENA ( A utomatic RE lease N otes gener A tor), an approach for the automatic generation of release notes. ARENA extracts changes from the source code, summarizes them, and integrates them with information from versioning systems and issue trackers. ARENA was designed based on the manual analysis of 990 existing release notes. In order to evaluate the quality of the release notes automatically generated by ARENA, we performed four empirical studies involving a total of 56 participants (48 professional developers and eight students). The obtained results indicate that the generated release notes are very good approximations of the ones manually produced by developers and often include important information that is missing in the manually created release notes

Analogy-Making as a Core Primitive in the Software Engineering Toolbox

An analogy is an identification of structural similarities and correspondences between two objects. Computational models of analogy making have been studied extensively in the field of cognitive science to better understand high-level human cognition. For instance, Melanie Mitchell and Douglas Hofstadter sought to better understand high-level perception by developing the Copycat algorithm for completing analogies between letter sequences. In this paper, we argue that analogy making should be seen as a core primitive in software engineering. We motivate this argument by showing how complex software engineering problems such as program understanding and source-code transformation learning can be reduced to an instance of the analogy-making problem. We demonstrate this idea using Sifter, a new analogy-making algorithm suitable for software engineering applications that adapts and extends ideas from Copycat. In particular, Sifter reduces analogy-making to searching for a sequence of update rule applications. Sifter uses a novel representation for mathematical structures capable of effectively representing the wide variety of information embedded in software. We conclude by listing major areas of future work for Sifter and analogy-making in software engineering.Comment: Conference paper at SPLASH 'Onward!' 2020. Code is available at https://github.com/95616ARG/sifte

Distinct Compartmentalization of the Chemokines CXCL1 and CXCL2 and the Atypical Receptor ACKR1 Determine Discrete Stages of Neutrophil Diapedesis.

Neutrophils require directional cues to navigate through the complex structure of venular walls and into inflamed tissues. Here we applied confocal intravital microscopy to analyze neutrophil emigration in cytokine-stimulated mouse cremaster muscles. We identified differential and non-redundant roles for the chemokines CXCL1 and CXCL2, governed by their distinct cellular sources. CXCL1 was produced mainly by TNF-stimulated endothelial cells (ECs) and pericytes and supported luminal and sub-EC neutrophil crawling. Conversely, neutrophils were the main producers of CXCL2, and this chemokine was critical for correct breaching of endothelial junctions. This pro-migratory activity of CXCL2 depended on the atypical chemokine receptor 1 (ACKR1), which is enriched within endothelial junctions. Transmigrating neutrophils promoted a self-guided migration response through EC junctions, creating a junctional chemokine "depot" in the form of ACKR1-presented CXCL2 that enabled efficient unidirectional luminal-to-abluminal migration. Thus, CXCL1 and CXCL2 act in a sequential manner to guide neutrophils through venular walls as governed by their distinct cellular sources.This work was supported by funds from the British Heart Foundation (FS/14/3/30518 to T.G. and S.N.), the People Programme (Marie Curie Actions) of the EU’s 7th Framework Programme (FP7/2007-2013) under REA grant agreement 608765 (to T.G. and S.N.), and by the Wellcome Trust (098291/Z/12/Z to S.N.). D.S. is supported by the CNIC, SAF2016-79040-R from the Spanish Ministerio de Ciencia, and ERC-2016-CoG 725091 from the European Research Council. M.T. and A.R. are supported by the Sinergia grant CRSII3_160719 of the Swiss National Science Foundation. G.G. is supported by the Wellcome Trust and the MRC. U.H.v.A. and A.T. are supported by the Ragon Institute of MGH, MIT and Harvard and the HMS Center for Immune Imaging

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to <90 ml per minute per 1.73 m2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], >300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years

Maintenance, and Enhancement, H.5.2 [Information Interfaces and Presentation] User Interfaces

3D Representations for Software Visualization The paper presents a new 3D representation for visualizing large software systems. The origins of this representation can be directly traced to the SeeSoft metaphor. This work extends these visualization mechanisms by utilizing the third dimension, texture, abstraction mechanism, and by supporting new manipulation techniques and user interfaces. By utilizing a 3D representation we can better represent higher dimensional data than previous 2D views. An overview of our prototype tool and its basic functionality is given. Applications of this method to particular software engineering tasks are also discussed

OpenFlights/Airline Route Mapper Route

<p>OpenFlights is a tool that lets you map your flights around the world, search and filter them in many ways. It’s also the name of the open-source project to build the tool. As of January 2012, the OpenFlights/Airline Route Mapper Route Database contains 59036 routes between 3209 airports on 531 airlines spanning the globe.</p